Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | PRKCA | P17252 | 2/20 | 0.30 |
| ▸ | PRKCE | Q02156 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16207207 | 0.92 | ALOX5 (0.36) | ALOX5ALDH1A1 | |
| SCHEMBL16207203 | 0.92 | ALOX5 (0.36) | ALOX5ALDH1A1 | |
| SCHEMBL20991379 | 0.92 | ALOX5 (0.42) | ALOX5LMNAALDH1A1HSD17B10MEN1 | |
| SCHEMBL15259625 | 0.88 | ALOX5 (0.55) | ALOX5LMNAALDH1A1HSD17B10MEN1 | |
| SCHEMBL15960434 | 0.88 | ALOX5 (0.46) | ALOX5LMNAALDH1A1HSD17B10MEN1 | |
| SCHEMBL15259575 | 0.88 | ALOX5 (0.55) | ALOX5LMNAALDH1A1HSD17B10MEN1 | |
| SCHEMBL15259624 | 0.88 | ALOX5 (0.55) | ALOX5LMNAALDH1A1HSD17B10MEN1 | |
| SCHEMBL15259577 | 0.88 | ALOX5 (0.55) | ALOX5LMNAALDH1A1HSD17B10MEN1 | |
| SCHEMBL15259595 | 0.88 | ALOX5 (0.55) | ALOX5LMNAALDH1A1HSD17B10MEN1 | |
| SCHEMBL15259591 | 0.88 | ALOX5 (0.55) | ALOX5LMNAALDH1A1HSD17B10MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230000943-A1 | METHOD OF INDUCING SYNAPTOGENESIS BY ADMINISTERING ANGIOTENSIN AND ANALOGUES THEREOF | Synaptogenix, Inc. (US) | 2023-01-05 | — | — | US | disclosed |
| US-20140315990-A1 | PKC ACTIVATORS AND COMBINATIONS THEREOF | COGNITIVE RESEARCH ENTERPRISES, INC. | 2014-10-23 | — | — | US | disclosed |
| US-20140315990-A1 | PKC ACTIVATORS AND COMBINATIONS THEREOF | COGNITIVE RESEARCH ENTERPRISES, INC. | 2014-10-23 | — | — | US | disclosed |
| US-20140235496-A1 | STIMULUS-ELICITED GENOMIC PROFILE MARKERS OF A NEURODEGENERATIVE CONDITION | BLANCHETTE ROCKEFELLER NEUROSCIENCES DRIVE (US) | 2014-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230000943-A1 | METHOD OF INDUCING SYNAPTOGENESIS BY ADMINISTERING ANGIOTENSIN AND ANALOGUES THEREOF | GAP43, SNAP29, SYNGR2 | ALOX5 443/4885LMNA 2577/4885ALDH1A1 4331/4885 |
| US-20140315990-A1 | PKC ACTIVATORS AND COMBINATIONS THEREOF | PRKCH, PRKCB, PRKCA | ALOX5 3192/4885LMNA 1261/4885ALDH1A1 4622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.